JPRN-UMIN000010296尚未招募未知
Objective assessment of fesoterodine for overactive bladder with benign prostatic hyperplasia - Fesoterodine for OAB with BPH
Dept. of Urology, Kyoto University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Post-void residual≥50ml 2) Urinary retention 3) Prostate cancer, neurogenic bladder, urethral stricture, chronic prostatitis, urinary infection, urinary tract calculi, interstitial cystitis 4) Patients who are contraindicated for fesoterodine administration 5) Within 2 weeks before entry, administration of contraindicated agents or treatments
研究者
相似试验
已完成
不适用
rodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladderneurogenic bladderJPRN-UMIN000037584Dokkyo Medical University77
已完成
4 期
Fesoterodine fumarate for the treatment of neurogenic bladdereurogenic detrusor overactivity (NDO)Nervous System DiseasesNeurogenic detrusor overactivity (NDO)ISRCTN22433402ational Rehabilitation Center85
已完成
不适用
The persistence of fesoterodine and the reasons for withdrawal from treatment of treatment-naive female patients with overactive bladder in the real-world clinical settingOveractive bladderJPRN-UMIN000038603Hokkaido Prefectural Esashi Hospital100
已完成
3 期
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.Overactive BladderNCT02614482Stéphane Bolduc26
已完成
3 期
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)Overactive BladderNCT00444925Pfizer1,712